Dolby Family Ventures — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
California Catalysts develops advanced materials and catalysts for hydrogen electrolysis using AI-driven discovery methods.
AI & Machine LearningCleantechEnergyNew MaterialsLos Angeles, US
Jim DiSanto(Co-founder, Board Director, Executive Consultant)
BoardNathan Lewis(Chief Scientific Advisor)
Co-investorsAcario InnovationMOL SwitchTSVCVoLo Earth VenturesMotus Ventures, Llc
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Anthony DePasqua(Executive Officer, Director)inTony DePasqua(President & CEO)Kevin Kalish(COO)Marcie Glicksman(VP Biology)William Gormley(CMO)Jason Camm(Director)
Co-investors20/20 HealthCare Partners LLCFlucas VenturesTachyon VenturesVU Venture Partners
Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHouston, US
Sameer Sheth(Founder)inSunil Sheth(Founder)Nick Halper(Chief Operating Officer)inSteve Goetz(Chief Technology Officer)inAnthony Arnold(Director)
BoardJacob Robinson(Co-founder & CEO)in
Co-investorsArboretum VenturesPsyMed VenturesTMC Venture FundCapital FactoryDivergent CapitalKdT Ventures+2 more
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Co-investorsAlta PartnersLongwood FundMission BiocapitalForbionService Provider Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.